Abstract
A major hurdle in drug delivery today is for the drug to reach inside the cell to exert its biological effect. Many drug candidates are hydrophilic and are therefore not able to cross the hydrophobic plasma membrane, which serves to protect the cell from foreign molecules and pathogens. One promising drug candidate is the hydrophilic and negatively charged short-interfering RNA (siRNA), known to degrade target mRNA 1,000-fold more efficiently than small molecule drugs. The delivery capacity of small cationic peptides called protein transduction domains or cell-penetrating peptides, suggested them to be suitable delivery vehicles for siRNA. However, it has proven troublesome to utilize the PTD–siRNA conjugates for mRNA degradation due to the characteristics of siRNA, often resulting in precipitation and aggregation. This chapter describes a recently reported delivery strategy, PTD–DRBD fusion protein siRNA delivery, where a double-stranded RNA-binding domain expressed as a fusion protein together with three TAT PTDs binds the siRNA, thus masking the negatively charged backbone and preventing aggregation. This new protocol results in noncytotoxic mRNA degradation even more effective than lipofection.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Frankel, A. D. and Pabo, C. O. (1988) Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55, 1189–1193.
Snyder, E. L. and Dowdy, S. F. (2004) Cell penetrating peptides in drug delivery. Pharm Res 21, 389–393.
Eguchi, A., Meade, B. R., Chang, Y. C., Fredrickson, C. T., Willert, K., Puri, N., and Dowdy, S. F. (2009) Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol 27, 567–571.
Vives, E., Brodin, P., and Lebleu, B. (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272, 16010–16017.
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., and Mello, C. C. (1998) Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature 391, 806–811.
St Johnston, D., Brown, N. H., Gall, J. G., and Jantsch, M. (1992) A conserved double-stranded RNA-binding domain. Proc Natl Acad Sci U S A 89, 10979–10983.
Bevilacqua, P. C. and Cech, T. R. (1996) Minor-groove recognition of double-stranded RNA by the double-stranded RNA-binding domain from the RNA-activated protein kinase PKR. Biochemistry 35, 9983–9984.
Wadia, J. S., Stan, R. V., and Dowdy, S. F. (2004) Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 10, 310–315.
Miyoshi, H., Blömer, U., Takahashi, M., Gage, F. H., and Verma, I. M. (1998) Development of a self-inactivating lentivirus vector. J Virol 72, 8150–8157.
Judge, A. D., Bola, G., Lee, A. C., and MacLachlan, I. (2006) Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 13, 494–505.
Acknowledgments
C.P.-A. was funded by a Knut & Alice Wallenberg’s Foundation Research Fellowship. A.E. was funded by a JSPS Research Fellowships for Young Scientists. This work was supported by the Leukemia and Lymphoma Society, the Pardee Foundation, California Institute of Regenerative Medicine, and Howard Hughes Medical Institute.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Palm-Apergi, C., Eguchi, A., Dowdy, S.F. (2011). PTD–DRBD siRNA Delivery. In: Langel, Ü. (eds) Cell-Penetrating Peptides. Methods in Molecular Biology, vol 683. Humana Press. https://doi.org/10.1007/978-1-60761-919-2_24
Download citation
DOI: https://doi.org/10.1007/978-1-60761-919-2_24
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-918-5
Online ISBN: 978-1-60761-919-2
eBook Packages: Springer Protocols